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average Medicare payment per individual in the ﬁ rst year following diagnosis is
$18,000 in year 2007. However, limited information is available regarding cost expen-
diture in commercial managed care plans. The purpose of this study was to report the
ﬁ rst year per patient cost expenditure after HNC diagnosis among commercially
insured lives. METHODS: A cross-sectional study was performed using data from a 
large U.S. commercial managed care claims database. Adult patients (q18 years)
diagnosed with HNC (based on ICD-9-CM codes) between January 1, 2006 to 
December 31, 2006 (index-period) without previous HNC diagnosis 12 months prior
to index date (ﬁ rst date of HNC diagnosis) were identiﬁ ed. At 12 months post index, 
total health care costs were extracted from medical claims and summarized at per 
patient level. RESULTS: 6,570 subjects were identiﬁ ed. The average age was 61 years
(o14.9) and 44% (n  2869) were females. Midwest (31%) and east (31%) regions 
had a higher (p  .01) representation, compared to south (20%) and west (18%). The
5 most common HNC sites constituted 70% of total diagnosis and consisted of 
unspeciﬁ ed HNC sites (24%; n  1588), lymph nodes (15%; n  1010), larynx (14%; 
n  898), connective and soft tissues (9%; n  579), and tongue (9%; n  507). Com-
monly utilized service types were physician (99%; n  6,486), other outpatient ancil-
lary/surgical (99%; n  6,474) and laboratory/diagnostic (90%; n  5,888). Subjects
had frequent visits to general practitioners (53%; n  3,509), internal medicine doctors 
(38%; n  2,523), and otolaryngologists (35%; n  2,291). Total average and median
health care cost per patient post HCN diagnosis were $29,608 (o77,500) and $7,347, 
respectively. CONCLUSIONS: This study found that the annual cost associated with 
HNC is higher in the commercial managed care population compared with what has 
been reported in the literature for Medicare expenditure.
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OBJECTIVES: In Mexico, breast cancer is the second cause of cancer mortality among 
females. For MBC patients resistant to AT, there are limited treatment options. There
is a scarcity of data regarding clinical management of this population and on the
treatment costs at this stage of the disease. The objective of this study was to estimate 
the cost of treatment patterns of care for MBC patients exposed to (AT) in the Mexican 
public health care sector. METHODS: Through medical chart review a retrospective 
cohort of adult female advanced breast cancer patients resistant to AT was con-
structed. The period was January 2004 to December 2007. Target population data 
ﬁ les were obtained from 600 patients out of 3 tertiary public hospitals in México. 
Treatments reviewed included surgery, radiation, hormonal therapy and cytotoxic
drug therapy RESULTS: Cytotoxic drug therapy was the treatment consuming the 
majority of resources (around 80% of total budget). Capecitabine, vinorelbine, ciclo-
phosfamide were the most common prescribed agents. Clinical drug therapy manage-
ment of the disease was notably different among the three hospitals in the sample. 
This difference translated into a disparity of prescription costs among the sites, ranging 
from US$6700 to $2824 for 1st treatment. Further research is needed to explain this 
variety of treatment patterns, however an initial query based on expert opinion sug-
gests that budget limitation among the hospitals is one of the main reasons. CONCLU-
SIONS: Chemotherapy treatment patterns and costs vary among the different 
hospitals. This ﬁ nding highlights a lack of standardized care for patients among hos-
pitals and suggests that differences are not only a reﬂ ection of scarcety of scientiﬁ c 
data and diversity of prescription preferences among physicians but also of economic
restrictions. Ultimately, there is a clear unmet medical need that needs to be addressed
through evidence based medicine alternatives that support efﬁ cacy and cost effective-
ness treatments.
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OBJECTIVES: To estimate total costs and assess primary cost drivers of treating newly 
diagnosed metastatic colorectal cancer (mCRC) after the introduction of biologic 
therapies. METHODS: Using a large claims database of a US nationally commercially
insured population, patients with newly diagnosed mCRC were identiﬁ ed from 2004
to 2006. Patients were followed from initial mCRC diagnosis to either death, disenroll-
ment, or December 31, 2006. Using methods from published literature, the follow-up
period for each patient was divided into three phases: diagnostic, treatment, and death. 
Average monthly costs for the three phases of disease were identiﬁ ed and asssigned as
inpatient, outpatient, emergency room (ER), or medication-related costs (including
chemotherapy and biologic agents). RESULTS: A total of 2322 newly diagnosed 
mCRC patients were identiﬁ ed. Outpatient care was the cost driver during the diag-
nostic (42.6%) and treatment (51.7%) phases. Inpatient care represented 39% of costs 
in the diagnostic phase largely due to surgical resection procedures (88.5%). Inpatient 
care was also the cost driver in the death phase (50.7%). Chemotherapies and biolog-
ics represented 15.6% and 16.2% of costs in the treatment phase; and 12.1% and 
11.7% of total costs across all phases of disease, respectively. CONCLUSIONS:
Inpatient and outpatient care were the key cost drivers in the medical management of 
mCRC. Biologics represented 16.2% of treatment phase costs and 11.7% of all costs 
incurred by mCRC patients across all phases of disease.
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OBJECTIVES: In Hungary, resources for anti-cancer chemotherapies are allocated 
from central budget, based on DRG accounts. The goal of current research was 
to investigate annual expenditures of ﬁ rst line chemotherapy protocols of metastatic 
colon cancer of Hungarian patients, especially the contribution of monoclonal 
antibodies. METHODS: A total of 1496 patients’ cost data have been collected.
Cost analysis of ﬁ rst line chemotherapy protocols has been conducted from the per-
spective of payer. Irinotecan, cetuximab, bevacizumab, capecitabine and oxaliplatin
containing regimens have been analysed for 12 consecutive months. RESULTS: Total 
expenditure of ﬁ rst line colon cancer chemotherapies was US$18.8 million for 12 
consecutive months. Average cost per patient was US$12,539 for the investigated
period. The share of patients, who have been treated by monoclonal antibodies con-
taining regimens was 16.8%, while cost of biologicals contributed 35% of total ﬁ rst 
line chemotherapies. CONCLUSIONS: The contribution of monoclonal antibodies
was relatively low in terms of treated patients in ﬁ rst line chemotherapy of colon
cancer. Furthermore, average duration of all chemotherapies were lower than reported 
in clinical trials, resulting suboptimal administration and cumulative dose of anti-
cancer compounds.
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OBJECTIVES: Costs associated with anthracycline-induced cardiotoxic events 
(CE) are not known. To compare cost associated with CE among three cohort
groups: anthracycline-containing-chemotherapy (ACC), no-anthracycline-containing-
chemotherapy (NACC), and no-chemotherapy (control) groups within a U.S. managed
care setting. METHODS: A retrospective cohort study was designed. Adult females
(q18) diagnosed with breast cancer between January 1, 2002 to December 31, 2005 
(index-period) were identiﬁ ed. Subjects with previous CE, breast cancer diagnosis, or 
anthracycline-use 12-months prior to index date were excluded. Index date was 
deﬁ ned as the ﬁ rst claim date for chemotherapy for ACC and NACC cohorts, and the
ﬁ rst non-chemotherapy medication claim date for controls. ACC and NACC were 
matched to controls by month of index date and year of birth. Total health care costs 
were extracted from medical and pharmacy claims and summarized at per patient per
year level. Cost of subjects developed CE were extracted from medical and pharmacy 
claims and were adjusted by using a gamma distributed generalized linear model with 
a log link function. RESULTS: A total of 21,106 subjects were classiﬁ ed as ACC (n 
 3,428), NACC (n  7,125) and controls (n  10,553). NACC cohort was signiﬁ cantly 
(p  .01) older (62 years o 12.5) compared to ACC (53 o 9.7) or control cohorts (59
o 12.5). ACC cohort had a higher (p  .01) degree of comorbidity, (1.8 o 0.8) com-
pared to NACC (1.6 o 0.9) or control (1.3 o 0.8) as measured by Charlson comorbid-
ity-index. At month 12 post index-date, 14% (n  485) of ACC and 5% (n  381) of 
NACC had CE compared to 3% (n  310) of controls. At 12 month post index, the 
unadjusted mean total health care costs per patient were $59,287, $20,528 and
$11,600, respectively. The adjusted total health care costs for subjects developed CE 
were $45,304,951, $17,727,884 and $11,591,263 for ACC, NACC and controls,
respectively. (p  .01). CONCLUSIONS: Health care cost for the ACC cohort was 
signiﬁ cantly higher than the NACC or controls cohorts.
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OBJECTIVES: The purpose of this study is to determine the economic beneﬁ t,
if any, of reducing waiting from the perspective of the Ontario health care system.
METHODS: An investigation in the Canadian scientiﬁ c and economics literature 
was conducted to determine the costs of assessment, diagnosis, treatment and 
follow-up of patients receiving care for a local recurrence. The risks associated 
with having a local recurrence, metastatic disease and terminal disease were also 
determined from the literature. The resulting cost of treatment was weighted according
to the risk of each health event, and by the associated risk of recurrence due to radio-
therapy delay. RESULTS: The cost of treating a recurrence, weighted according to risk
of progression to more severe disease, was approximately $36,000 within the model.
The associated incremental cost savings per week of waiting reduction was $72.49. 
Sensitivity analysis was conducted around the estimate. CONCLUSIONS: The cost 
savings associated with avoiding one breast cancer recurrence is approximately
$36,000 from the perspective of the health care system. Reducing waiting for radio-
therapy by one week may save the health care system $72 per patient in downstream
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costs. In a health care system like Ontario’s, which treats 2800 new breast cancer 
patients per year, this may represent a signiﬁ cant reduction in operation cost. These
savings should be considered in context of how much resource investment is required
to reduce waiting.
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OBJECTIVES: Squamous cell carcinoma of the head and neck (SCCHN) can be a 
devasting disease. Cetuximab has recently been shown to improve locoregional control
(LRC) and reduce mortality in locally and regionally advanced disease. The objective
of the study is to estimate the incremental cost-utility of cetuximab plus radiotherapy 
(CxRT) versus cisplatin plus radiotherapy (CsRT) among platinum eligible patients
and versus RT alone in platinum ineligible patients in Canada. METHODS: A lifetime 
transition model was developed with four health states: 1) acute treatment phase; 2)
LRC; 3) disease progression and 4) death. Adverse events were accounted for in the
ﬁ rst two states. Efﬁ cacy of treatment (LRC and overall survival) was obtained from 
the literature. Based on network meta-analyses, CsRT and CxRT were assumed to
have equal efﬁ cacy. Resource use was obtained from published literature and clinical 
expert opinion. The perspective adopted was that of a provincial ministry of health
or cancer agency. Utilities were obtained from a previous study of UK oncology nurses.
Costs (CDN$2008) and outcomes were discounted at 5% annually. Incremental cost-
effectiveness ratios (ICERs) were reported with one-way and probabilistic sensitivity
analyses performed to assess robustness of results. A priori sub-group analyses were 
carried out by baseline Karnofsky Performance Scores (KPS). RESULTS: Among 
all patients (KPS 60–100), the ICERs comparing CxRT to RT were $19,740/QALY 
(95% CI: $11,122 to $695,295) among platinum ineligible patients and for CxRT vs. 
CsRT, $99,147/QALY (95% CI: $75,998 to $148,951) among platinum eligible 
patients. ICERs decreased with increasing KPS scores. At a willingness-to-pay of 
$50,000 among platinum-ineligible patients and $100,000 among platinum-eligible
patients, the likelihood that CxRT is cost-effective is 90% and 45% respectively. Sen-
sitivity analyses indicated that time horizon and assumptions about CsRT effectiveness
had the largest impact on results. CONCLUSIONS: Cetuximab is an economically
attractive option for SCCHN patients.
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OBJECTIVES: To determine incremental costs and life expectancy of adding bevaci-
zumab (bev) to an irinotecan plus infusional 5-ﬂ uorouracil/leucovorin (5-FU/LV) 
regimen (FOLFIRI) for the ﬁ rst-line treatment of patients with metastatic colorectal 
cancer (MCRC) in the UK. METHODS: We performed a decision analysis with a
THREE-health-state area under the curve model to explore the effects of adding bev 
treatment to an existing FOLFIRI-based regimen. The model structure was based on
a published model by National Institute of Technology Excellence (NICE), UK. Pro-
gression-free (PFS) and overall survival (OS) data were derived from clinical trials 
comparing bevirinotecan and 5-FU/LV (IFL) with IFL alone. The impact on OS for 
bevFOLFIRI was included through an indirect comparison of hazard ratios (HRs)
between bevmIFL versus bevFOLFIRI (HR for death: 1.79; 95% CI: 1.12–2.88).
Treatment effect for bevFOLFIRI was maintained during the 40-month clinical
follow-up. The FOLFIRI PFS was created by applying the HR from IFL versus
FOLFIRI (HR for progression or death: 1.51, 95% CI: 1.16–1.97) to the IFL PFS. 
Outcomes included life years, QALYs, direct costs and incremental cost-effectiveness 
ratios (ICERs). A life-time horizon (8 years) was used. Cost and outcomes were dis-
counted by 3.5% per annum. Both deterministic and probabilistic sensitivity analyses 
were performed. RESULTS: The estimated discounted life expectancy for bevFOLFIRI-
treated patients was 2.62 years (undiscounted: 2.77 years) versus 1.58 years (undis-
counted: 1.63 years) in the FOLFIRI arm. The discounted costs in the 2 arms were
a49,798 and a23,698, respectively. The discounted ICER was a25,045 per life-year
gained and a40,532 per QALY gained. Sensitivity analysis on key variables showed
that assumptions of size (HR) and duration of treatment effect were the most inﬂ u-
ential factors for the ICER. CONCLUSIONS: BevFOLFIRI versus current FOLFIRI-
based treatment regimens for MCRC increases survival for these patients and is a cost
effective treatment option.
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OBJECTIVES: To model expected mean incremental costs and life expectancy of 
adding bevacizumab (bev) to an irinotecan plus infusional 5-ﬂ uorouracil/leucovorin
(5-FU/LV) regimen (FOLFIRI) for the ﬁ rst-line treatment of patients with metastatic 
colorectal cancer (MCRC) in Sweden. METHODS: A 3-health-state model explored 
the effects of adding bev treatment to an existing FOLFIRI-based regimen. The model
structure was based on one published by National Institute for Health and Clinical
Excellence (NICE) UK, which applies to guidelines established by the Swedish Phar-
maceutical and Dental Beneﬁ ts Board. Progression-free (PFS) and overall survival (OS)
data are derived from clinical trials comparing bevirinotecan and 5-FU/LV (IFL) with 
IFL alone. The impact on OS for bevFOLFIRI was included through an indirect 
comparison of hazard ratios (HRs) between bevmIFL versus bevFOLFIRI (HR for 
death: 1.79; 95%CI: 1.12–2.88). Treatment effect for bevFOLFIRI was maintained
during the 40-month clinical follow-up. The FOLFIRI PFS was created by applying 
the HR from IFL versus FOLFIRI (HR for progression or death: 1.51, 95%CI: 1.16–
1.97) to the IFL PFS. Outcomes included life years, QALYs, direct costs and incre-
mental cost-effectiveness ratios (ICERs). A life-time horizon (eight years) was used.
Cost and outcomes were discounted by 3% per annum. RESULTS: The estimated 
mean life expectancy for bevFOLFIRI-treated patients was 2.64 years (discounted; 
2.77 years undiscounted) versus 1.58 years (discounted; 1.63 years undiscounted) in 
the FOLFIRI arm. The discounted costs in the 2 arms were 525,404 SEK and 245,775
SEK, respectively. The discounted ICER was 264,689 SEK/life-year gained and 
428,519 SEK/QALY gained. Sensitivity analysis on key variables showed that assump-
tions of size (HR) of treatment effect and duration of treatment effect were the most 
critical factors for the ICER. CONCLUSIONS: BevFOLFIRI versus current FOLFIRI-
based treatment regimens for MCRC is predicted to increase survival for these patients 
and also be a cost-effective treatment option in Sweden.
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OBJECTIVES: In EGF100151, lapatinib plus capecitabine (LC) improved time to 
progression (TTP) vs C-only (Median 27.1 vs 18.6 wks, HR  0.57, p  0.001) in 
women with ErbB2 MBC who had received prior CT with TZ, anthracyclines, and 
taxanes. In GBG26, TZ plus capecitabine (TZC) improved TTP vs C-only in ErbB2
MBC patients with prior TZ and a1 prior courses of palliative CT (n  74 vs 77, 
median 36.9 vs 24.3 wks, HR  0.69, p  0.034). Because 50% of EGF100151 
patients had received q4 prior lines of CT, results of EGF100151 and GBG26 are not 
directly comparable. The objective of this analysis was to evaluate (1) the CE (cost 
per quality-adjusted life year [QALY] gained) of TZC vs C-only in GBG26 and 
(2) the CE of LC vs C-only in a subgroup of comparable EGF100151 patients 
(3 CT, n  31 vs 37, TTP: Median 49.4 vs 19.7 wks, HR  0.37, p  0.0059, OS: 
Median 87.3 vs 55.1 wks, HR  0.51, p  0.0140). METHODS: Trial-based survival 
analyses were conducted of GBG26 patients and of EGF100151 patients with 3 CT, 
with progression-free survival (PFS) and OS for each treatment arm estimated by
ﬁ tting Weibull survival functions to failure-time data. A UK National Health Service 
perspective was employed. Costs and utilities were estimated using data from 
EGF100151 and the literature. RESULTS: The increase in QALYs for LC vs C-only 
among EGF100151 patients with 3 CT is 0.462; for TZC vs C-only in GBG26,
0.167. The increase in costs for LC vs C-only among EGF100151 patients with 3 
CT is a24,094; for TZC vs C-only in GBG26, a23,198. CE with LC vs C-only 
among EGF100151 patients with 3 CT is a52,152/QALY; for TZC vs C-only in 
GBG26, a138,910/QALY. CONCLUSIONS: In TZ-refractory ErbB2 MBC patients
with limited CT exposure, CE of LC vs C-only may be more favorable than CE of 
TZC vs C-only.
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OBJECTIVES: Calculate life expectancy and quality of life of geﬁ tinib versus docetaxel 
in the treatment of non-small-cell lung cancer in a Mexican public institution (ISSSTE).
METHODS: A Discrete Event Simulation model was designed to emulate probabilities 
of having one or more adverse events at the same time when in treatment for
